Jefferies maintains a 'Hold' on AVEO Pharmaceuticals (AVEO); Update From 2012 Boston Healthcare Summit

Jefferies maintains a 'Hold' on AVEO Pharmaceuticals (NASDAQ: AVEO) price target of $11.00.

Analyst, Thomas Wei, said, "AVEO management team provided an incremental positive update to investors on the regulatory controversy and planned analyses it hopes will address an unfavorable overall survival trend for tivozanib in its Phase 3 renal cell cancer trial. While we accept AVEO’s theory for the OS findings and are incrementally positive on the details of the analyses, we remain uncertain how the FDA will assess the situation."

For an analyst ratings summary and ratings history on AVEO Pharmaceuticals click here. For more ratings news on AVEO Pharmaceuticals click here.

Shares of AVEO Pharmaceuticals closed at $8.73 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies Starts Faraday Copper Corp (FDY:CN) (CPPKF) at Buy
• UBS Upgrades Sartorius AG (SRT3:GR) (SARTF) to Buy
• Morgan Stanley Upgrades HDB Financial Services (HDBFS:IN) to Overweight